Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets

£48.00

Description
Reviews (0)

Pharmaqo Labs Cialis Tadalafil 20mg x 50 Tablets

Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets delivers a precise oral formulation of Tadalafil, a potent phosphodiesterase type 5 (PDE5) inhibitor widely utilized in vascular and endothelial research. This compound belongs to the same therapeutic class as Sildenafil (Viagra), functioning through enhanced nitric oxide-mediated vasodilation. The 20mg tablet strength provides substantial research flexibility, enabling examination of dose-response relationships and extended duration protocols. Each package contains 50 tablets, supporting longitudinal studies on vascular function, hemodynamic parameters, and erectile physiology in controlled models. Studies utilizing Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets examine its effects on smooth muscle relaxation, blood flow dynamics, and tissue perfusion.

Tadalafil distinguishes itself through extended duration of action compared to alternative PDE5 inhibitors. The compound’s half-life of approximately 17.5 hours supports research into sustained vascular effects and prolonged therapeutic windows. This characteristic proves particularly valuable for studies examining chronic dosing regimens, tissue oxygenation, and the metabolic effects of sustained PDE5 inhibition. The 20mg strength represents a robust research dose, allowing for precise titration and examination of both efficacy and safety parameters.

The mechanism centers on nitric oxide signaling pathways. Sexual stimulation triggers nitric oxide release in vascular endothelium, activating guanylate cyclase and elevating cyclic GMP levels. Tadalafil potentiates this response by inhibiting PDE5, the enzyme responsible for cGMP degradation. The resulting sustained elevation of cGMP promotes smooth muscle relaxation and enhanced blood flow to target tissues. Research applications include examination of penile hemodynamics, pulmonary vascular resistance, lower urinary tract symptoms, and systemic endothelial function.

Mechanism of Action

Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets operates through a precise enzymatic inhibition mechanism:

PDE5 Enzyme Blockade: Tadalafil selectively inhibits phosphodiesterase type 5, preventing cGMP hydrolysis.
Nitric Oxide Potentiation: Enhances NO–mediated vasodilation in response to physiological stimulation.
Smooth Muscle Relaxation: Sustained cGMP elevation promotes calcium sequestration and muscular relaxation.
Enhanced Blood Flow: Vasodilation increases perfusion to tissues with PDE5-expressing vasculature.
Extended Duration: 17.5-hour half–life supports prolonged research windows compared to alternative compounds.

Metabolic Impact

Research utilizing Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets reveals significant physiological effects:

Vascular Function: Improved endothelial function and reduced arterial stiffness in studied models.
Pulmonary Hemodynamics: Reduced pulmonary vascular resistance relevant to hypertension research.
Lower Urinary Tract: Relaxed smooth muscle in prostate and bladder neck regions.
Exercise Capacity: Enhanced oxygen delivery and utilization in cardiopulmonary studies.
Hepatic Metabolism: Primarily CYP3A4 substrate with minor CYP2C9 involvement.

Key Features

Extended Half-Life: 17.5–hour duration supports sustained effect research.
Potent PDE5 Inhibition: High selectivity minimizes off-target effects on other phosphodiesterase isoforms.
Flexible Research Dosing: 20mg tablets enable precise titration and dose-response studies.
Extended Supply: 50-tablet format supports longer protocols without resupply.
Rapid Onset: Effects observed within 30 minutes of administration.
Well-Established Profile: Extensive research history supports reliable experimental design.
Verified Purity Standards: Manufactured under strict pharmaceutical protocols with independent batch testing.

Product Specifications

Product Name: Pharmaqo Labs Cialis Tadalafil
Active Ingredient: Tadalafil
Chemical Classification: Phosphodiesterase Type 5 (PDE5) Inhibitor
Dosage Strength: 20mg per tablet
Pack Size: 50 tablets
CAS Number: 171596-29-5
Molecular Formula: C22H19N3O4
Appearance: Yellow to orange-yellow almond-shaped tablets
Onset of Action: Approximately 30 minutes
Duration of Effect: Up to 36 hours
Storage Requirements: Store at 15°C-25°C; protect from light, moisture, and heat
Shelf Life: 3 years from manufacture date (as indicated on packaging)
Legal Status: Prescription medication / Research chemical (Regulations vary by jurisdiction)

Where to Buy

Authorized Suppliers Only: Purchase exclusively from verified Pharmaqo Labs distributors with documented authorization.
Batch Verification: Verify unique batch codes through official Pharmaqo Labs channels before use.
Visual Inspection: Authentic packaging features professional labeling, intact seals, and uniform tablets free of defects.
Avoid Unverified Sources: Do not purchase from social media, underground forums, or vendors lacking proof of authenticity.

Side Effects

Research and clinical data indicate the following potential effects:

Common: Headache, back pain, dyspepsia, flushing, nasal congestion, myalgia.
Ocular: Visual disturbances, color perception changes, conjunctival hyperemia.
Cardiovascular: Hypotension, tachycardia, chest pain in susceptible models.
Rare: Priapism, sudden hearing loss, non-arteritic anterior ischemic optic neuropathy.
Drug Interactions: Contraindicated with nitrates; caution with alpha–blockers and CYP3A4 inhibitors.

Conclusion

Pharmaqo Labs Cialis Tadalafil 20mg x 50 tablets represents a critical research tool for investigators examining vascular physiology, endothelial function, and PDE5-mediated signaling pathways. The compound’s extended duration distinguishes it from alternative agents, enabling unique experimental designs focused on sustained rather than acute effects. The precise 20mg dosing, substantial 50-tablet supply, and verified pharmaceutical-grade manufacturing ensure experimental reliability across diverse research applications. While generally well-tolerated, researchers must account for potential cardiovascular, ocular, and musculoskeletal effects in protocol design. The requirement for physiological stimulation to initiate the NO-cGMP cascade underscores the importance of appropriate experimental conditions. Proper sourcing through authorized distributors guarantees authenticity, protecting research investments and ensuring valid scientific outcomes. As with all potent vasoactive compounds, adherence to local regulations, ethical guidelines, and safety protocols remains essential for responsible scientific inquiry.